ConductScience.org, home

Comparison · NCT04706507-4da30e12

IV Ganciclovir vs Placebo: To Evaluate Whether Mortality and Time to Death in the 28 Days is Different Among Ganciclovir Recipients Relative to Placebo Recipients, Respectively.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. IV Ganciclovir vs Placebo: To Evaluate Whether Mortality and Time to Death in the 28 Days is Different Among Ganciclovir Recipients Relative to Placebo Recipients, Respectively. Trial comparisons, record NCT04706507-4da30e12. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04706507-4da30e12

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3210.240.415wilson
Risk in group 20.1310.07840.212wilson
Risk difference, group 1 minus group 20.1890.07510.297newcombe hybrid score
Risk ratio, group 1 over group 22.441.374.35log
Odds ratio, group 1 over group 23.121.536.36log
Number needed to treat, for one more participant with the outcome on IV Ganciclovir than on Placebo5.283.3713.3from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1IV Ganciclovir5mg/kg IV twice daily for 5 days, then followed by IV ganciclovir once daily until hospital discharge34106OG000
Group 2Placebonormal saline IV twice daily for 5 days, then followed by IV normal saline once daily until hospital discharge1399OG001

Outcome

Type
SECONDARY
Title
To Evaluate Whether Mortality and Time to Death in the 28 Days is Different Among Ganciclovir Recipients Relative to Placebo Recipients, Respectively.
Description
This is a time to event outcome with death as the event and censoring at the time of study termination if the participant is alive at 28 days. The hazard ratio and Cox proportional hazards models are used for this endpoint.
Time frame
at study day 28
Population
Includes all participant enrolled, eligible, and evaluable (not replaced).

Source ClinicalTrials.gov

Trial

Title
Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis
NCT number
NCT04706507
Phases
PHASE3
Conditions
Acute Respiratory Failure
Interventions
IV Ganciclovir, Normal saline
Lead sponsor
Fred Hutchinson Cancer Center
Results first posted
2025-12-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04706507-4da30e12